Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Fortress Biotech (FBIO) Research & Development (2016 - 2025)

Historic Research & Development for Fortress Biotech (FBIO) over the last 13 years, with Q3 2025 value amounting to $208000.0.

  • Fortress Biotech's Research & Development fell 9779.8% to $208000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $22.0 million, marking a year-over-year decrease of 6127.53%. This contributed to the annual value of $56.6 million for FY2024, which is 4434.33% down from last year.
  • According to the latest figures from Q3 2025, Fortress Biotech's Research & Development is $208000.0, which was down 9779.8% from $8.1 million recorded in Q2 2025.
  • In the past 5 years, Fortress Biotech's Research & Development registered a high of $43.1 million during Q4 2021, and its lowest value of $208000.0 during Q3 2025.
  • Moreover, its 5-year median value for Research & Development was $24.8 million (2024), whereas its average is $22.7 million.
  • Per our database at Business Quant, Fortress Biotech's Research & Development soared by 13968.16% in 2021 and then crashed by 9779.8% in 2025.
  • Fortress Biotech's Research & Development (Quarter) stood at $43.1 million in 2021, then decreased by 18.43% to $35.1 million in 2022, then plummeted by 72.23% to $9.8 million in 2023, then decreased by 0.66% to $9.7 million in 2024, then plummeted by 97.85% to $208000.0 in 2025.
  • Its Research & Development stands at $208000.0 for Q3 2025, versus $8.1 million for Q2 2025 and $3.9 million for Q1 2025.